Celltech-Merck collaboration: phosphodiesterase 4 inhibitor for respiratory disease

• Oral anti-inflammatory agent

  • once-daily
  • potent & specific

• Unique in class

  • no emesis

• Ph II programme (initiated 2001)

  • asthma
    • also in combination with SINGULAIR
  • chronic obstructivepulmonary disease

Previous slide

Next slide

Back to first slide

View graphic version